Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_4
2
50%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (50.0%)
Phase 42 (50.0%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Clopidogrel And Ticagrelor in Healthy Subjects

NCT02086903
terminatedphase_4

Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.

NCT00421252
completedphase_3

Prasugrel With Lower Dose - Loading Dose

NCT02070159
completedphase_4

Safety and Efficacy of Three Different Loading Doses of Clopidogrel, in Patients With Acute Myocardial Infarction

NCT00882739

Clinical Trials (4)

Showing 4 of 4 trials
NCT02086903Phase 3

Clopidogrel And Ticagrelor in Healthy Subjects

Completed
NCT00421252Phase 4

Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.

Terminated
NCT02070159Phase 3

Prasugrel With Lower Dose - Loading Dose

Completed
NCT00882739Phase 4

Safety and Efficacy of Three Different Loading Doses of Clopidogrel, in Patients With Acute Myocardial Infarction

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4